Profound Medical Corp. (TSE:PRN – Get Rating) – Stock analysts at Jefferies Financial Group cut their Q2 2022 earnings estimates for shares of Profound Medical in a research note issued to investors on Monday, May 9th. Jefferies Financial Group analyst Z. Weiner now anticipates that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.41). Jefferies Financial Group also issued estimates for Profound Medical’s Q3 2022 earnings at ($0.37) EPS, Q4 2022 earnings at ($0.36) EPS, FY2022 earnings at ($1.75) EPS, FY2023 earnings at ($1.27) EPS and FY2024 earnings at ($0.29) EPS.
Profound Medical (TSE:PRN – Get Rating) last released its earnings results on Thursday, March 3rd. The company reported C($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.44) by C($0.18). The business had revenue of C$1.26 million for the quarter, compared to analyst estimates of C$3.52 million.
PRN opened at C$9.01 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 18.56 and a quick ratio of 16.50. The company’s 50 day simple moving average is C$10.56 and its two-hundred day simple moving average is C$12.63. Profound Medical has a 1-year low of C$8.00 and a 1-year high of C$23.67. The firm has a market capitalization of C$187.23 million and a price-to-earnings ratio of -4.62.
Profound Medical Company Profile (Get Rating)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.